Thu, May 25, 12:13 PM, Zacks
Aerie's Ophthalmic Candidate Positive in Registration Trial
Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.
Thu, May 25, 8:42 AM, Zacks
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).